AAAAAA
Results:
1-13
|
Results: 13
Authors:
LAZARUS SC
LEE T
KEMP JP
WENZEL S
DUBE LM
OCHS RF
CARPENTIER PJ
LANCASTER JF
Citation: Sc. Lazarus et al., SAFETY AND CLINICAL EFFICACY OF ZILEUTON IN PATIENTS WITH CHRONIC ASTHMA, American journal of managed care, 4(6), 1998, pp. 841-848
Authors:
DAHLEN B
NIZANKOWSKA E
SZCZEKLIK A
ZETTERSTROM O
BOCHENEK G
KUMLIN M
MASTALERZ L
PINIS G
SWANSON LJ
BOODHOO TI
WRIGHT S
DUBE LM
DAHLEN SE
Citation: B. Dahlen et al., BENEFITS FROM ADDING THE 5-LIPOXYGENASE INHIBITOR ZILEUTON TO CONVENTIONAL THERAPY IN ASPIRIN-INTOLERANT ASTHMATICS, American journal of respiratory and critical care medicine, 157(4), 1998, pp. 1187-1194
Authors:
WONG SL
ODEA RF
DUBE LM
AWNI WM
Citation: Sl. Wong et al., EFFECTS OF ABT-761, A NOVEL 5-LIPOXYGENASE INHIBITOR, ON THE PHARMACOKINETICS OF A SINGLE-DOSE OF ETHINYL ESTRADIOL AND LEVONORGESTREL IN HEALTHY FEMALE VOLUNTEERS, Journal of clinical pharmacology, 38(7), 1998, pp. 642-648
Authors:
SCHWARTZ HJ
PETTY T
DUBE LM
SWANSON LJ
LANCASTER JF
Citation: Hj. Schwartz et al., A RANDOMIZED CONTROLLED TRIAL COMPARING ZILEUTON WITH THEOPHYLLINE INMODERATE ASTHMA, Archives of internal medicine, 158(2), 1998, pp. 141-148
Authors:
DUBUSKE LM
GROSSMAN J
DUBE LM
SWANSON LJ
LANCASTER JF
BERGER W
CHAROUS BL
CRINER G
DAUL C
EDWARDS T
FINK JN
FLESCHER J
HOWLAND WC
KAISER HB
KORENBLAT PE
KUSSIN PS
LANG D
LIGHT R
NATHAN R
PIEN L
PLATTSMILLS TAE
RAMSDELL J
SCARDELLA AT
SCHENKEL EJ
SELNER J
SILVERS WS
CARPENTIER PJ
SWANSON SW
MANSKI RP
RUFF DD
Citation: Lm. Dubuske et al., RANDOMIZED TRIAL OF ZILEUTON IN PATIENTS WITH MODERATE ASTHMA - EFFECT OF REDUCED DOSING FREQUENCY AND AMOUNTS ON PULMONARY-FUNCTION AND ASTHMA SYMPTOMS, American journal of managed care, 3(4), 1997, pp. 633-640
Authors:
AWNI WM
LOCKE C
DUBE LM
CAVANAUGH JH
Citation: Wm. Awni et al., EVALUATION OF THE DIURNAL-VARIATION IN THE PHARMACOKINETICS OF ZILEUTON IN HEALTHY-VOLUNTEERS, Journal of clinical pharmacology, 37(5), 1997, pp. 388-394
Authors:
AWNI WM
CAVANAUGH JH
LEESE P
KASIER J
CAO GL
LOCKE CS
DUBE LM
Citation: Wm. Awni et al., THE PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION BETWEEN ZILEUTON AND TERFENADINE, European Journal of Clinical Pharmacology, 52(1), 1997, pp. 49-54
Authors:
HAWKEY CJ
DUBE LM
ROUNTREE LV
LINNEN PJ
LANCASTER JF
KREJS GJ
GANGL A
VANTRAPPEN G
BARBIER F
POLESKI M
MARTIN F
SAIBIL F
RASKMADSEN J
LAURITSEN K
BARBIER JP
RAMBAUD JC
COUTURIER D
CASPARY WF
GOEBELL H
DOELLE W
STROHMEYER G
SWOBODNIK W
RAEDLER A
SKANDALIS N
VANDEVENTER SJH
SNEL P
WRIGHT JP
GESSULL MA
GONZALES F
OBRADOR A
HALTER F
KAYASSEH L
OMORAIN C
REES WO
Citation: Cj. Hawkey et al., A TRIAL OF ZILEUTON VERSUS MESALAZINE OR PLACEBO IN THE MAINTENANCE OF REMISSION OF ULCERATIVE-COLITIS, Gastroenterology, 112(3), 1997, pp. 718-724
Authors:
LIU MC
DUBE LM
LANCASTER J
Citation: Mc. Liu et al., ACUTE AND CHRONIC EFFECTS OF A 5-LIPOXYGENASE INHIBITOR IN ASTHMA - A6-MONTH RANDOMIZED MULTICENTER TRIAL, Journal of allergy and clinical immunology, 98(5), 1996, pp. 859-871
Authors:
OCONNOR BJ
GODARD P
DUBE LM
SWANSON LJ
MAKI R
Citation: Bj. Oconnor et al., THE COMPARATIVE EFFECT OF ZILEUTON, A 5-LIPOXYGENASE INHIBITOR, PLUS LOW-DOSE INHALED BECLOMETHASONE VS HIGHER DOSE BECLOMETHASONE FOR ASTHMA, Journal of allergy and clinical immunology, 97(1), 1996, pp. 271-271
Authors:
AWNI WM
CAO G
KASIER JF
LOCKE CS
MACHINIST JM
DUBE LM
Citation: Wm. Awni et al., THE PHARMACOKINETIC PHARMACODYNAMIC INTERACTION BETWEEN ZILEUTON AND TERFENADINE/, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 61-61
Authors:
AWNI WM
GRANNEMAN GR
LOCKE CS
BRANDWEIN SR
DUBE LM
Citation: Wm. Awni et al., POPULATION PHARMACOKINETICS OF ZILEUTION, A SELECTIVE 5-LIPOXYGENASE INHIBITOR, IN PATIENTS WITH RHEUMATOID-ARTHRITIS, European Journal of Clinical Pharmacology, 48(2), 1995, pp. 155-160
Authors:
AWNI WM
CAVANAUGH JH
GRANNEMAN GR
SCHNECK DW
DUBE LM
Citation: Wm. Awni et al., DIURNAL-VARIATION IN THE PHARMACOKINETICS OF ZILEUTON IN HUMANS, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 199-199
Risultati:
1-13
|